BR9408305A - Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos - Google Patents

Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos

Info

Publication number
BR9408305A
BR9408305A BR9408305A BR9408305A BR9408305A BR 9408305 A BR9408305 A BR 9408305A BR 9408305 A BR9408305 A BR 9408305A BR 9408305 A BR9408305 A BR 9408305A BR 9408305 A BR9408305 A BR 9408305A
Authority
BR
Brazil
Prior art keywords
hiv
hiv infection
compounds
treatment
aids
Prior art date
Application number
BR9408305A
Other languages
English (en)
Inventor
Joel R Huff
Joseph P Vacca
Bruce D Dorsey
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9408305A publication Critical patent/BR9408305A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
BR9408305A 1993-12-15 1994-12-12 Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos BR9408305A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16801393A 1993-12-15 1993-12-15
US17047593A 1993-12-20 1993-12-20
PCT/US1994/014187 WO1995016688A1 (en) 1993-12-15 1994-12-12 Hiv protease inhibitors

Publications (1)

Publication Number Publication Date
BR9408305A true BR9408305A (pt) 1997-08-26

Family

ID=26863718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9408305A BR9408305A (pt) 1993-12-15 1994-12-12 Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos

Country Status (19)

Country Link
US (2) US5646148A (pt)
EP (1) EP0734387B1 (pt)
JP (1) JP3000564B2 (pt)
KR (1) KR100234863B1 (pt)
CN (1) CN1046727C (pt)
AT (1) ATE215952T1 (pt)
AU (1) AU692509B2 (pt)
BG (1) BG62093B1 (pt)
BR (1) BR9408305A (pt)
CA (1) CA2178760C (pt)
CZ (1) CZ288312B6 (pt)
DE (1) DE69430385T2 (pt)
ES (1) ES2174921T3 (pt)
FI (1) FI962488A (pt)
HU (1) HUT74681A (pt)
NZ (1) NZ278201A (pt)
PL (1) PL314984A1 (pt)
SK (1) SK75796A3 (pt)
WO (1) WO1995016688A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270808B1 (en) 1995-11-13 2001-08-07 Gerard Voerman Anti-viral isolates obtainable from leeches
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
TW438799B (en) * 1997-05-29 2001-06-07 Merck & Co Inc HIV protease inhibitor
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
CO4970782A1 (es) * 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
FR2780649B1 (fr) 1998-07-06 2001-03-09 Univ Paris Vii Denis Diderot Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
GB2341385A (en) 1998-09-14 2000-03-15 Merck & Co Inc Recovery of iodide from chemical process waste water
US6440946B1 (en) * 1999-02-25 2002-08-27 Takeda Chemical Industries, Ltd. Multiple-agents-binding compound, production and use thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
DE60036961T2 (de) 1999-11-24 2008-08-28 Merck & Co., Inc. Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
US6482952B2 (en) 2000-06-20 2002-11-19 Merck & Co., Inc. Process for preparing acetonides
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
AU2003270727A1 (en) * 2002-09-17 2004-04-08 Luna Innovations, Inc. Remote temperature sensing of small volume and related apparatus thereof
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN108178764A (zh) * 2018-01-09 2018-06-19 天津科技大学 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
DK0541168T3 (da) * 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
KR100311551B1 (ko) * 1993-03-31 2001-12-28 폴락 돈나 엘. Aids 치료용 약제학적 배합물 중의 hiv 프로테아제 억제제

Also Published As

Publication number Publication date
BG62093B1 (bg) 1999-02-26
DE69430385T2 (de) 2002-11-07
CN1142827A (zh) 1997-02-12
BG100643A (bg) 1997-02-28
FI962488A0 (fi) 1996-06-14
PL314984A1 (en) 1996-09-30
US5646148A (en) 1997-07-08
EP0734387B1 (en) 2002-04-10
CN1046727C (zh) 1999-11-24
EP0734387A4 (en) 1997-03-05
AU692509B2 (en) 1998-06-11
DE69430385D1 (de) 2002-05-16
HU9601649D0 (en) 1996-08-28
CA2178760A1 (en) 1995-06-22
FI962488A (fi) 1996-06-14
WO1995016688A1 (en) 1995-06-22
CZ288312B6 (en) 2001-05-16
CZ158696A3 (en) 1996-11-13
HUT74681A (en) 1997-01-28
CA2178760C (en) 2000-08-01
EP0734387A1 (en) 1996-10-02
KR100234863B1 (ko) 1999-12-15
US5807841A (en) 1998-09-15
AU1433195A (en) 1995-07-03
ATE215952T1 (de) 2002-04-15
SK75796A3 (en) 1997-05-07
NZ278201A (en) 1998-01-26
ES2174921T3 (es) 2002-11-16
JPH09506619A (ja) 1997-06-30
JP3000564B2 (ja) 2000-01-17

Similar Documents

Publication Publication Date Title
AU2725392A (en) Hiv protease inhibitors
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
BR9408305A (pt) Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos
ATE252081T1 (de) Neue hiv-protease-inhibitoren
MY109834A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
BR9406503A (pt) Combinação de compostos composição farmacêutica e processos para tratar aids para evitar e para tratar infecção por HIV e para inibir protease de HIV
WO1996000068A3 (en) Combination therapy for hiv infection
EP0774969B8 (en) Hiv protease inhibitor combination
WO2002096359A3 (en) Piperazine pentanamide hiv protease inhibitors

Legal Events

Date Code Title Description
FA Application withdrawn